Skip to main content

Table 1 Clinical information of patients with benign and malignant prostate disease

From: MRI-based radiomics models to assess prostate cancer, extracapsular extension and positive surgical margins

 

Benign

Malignant

Number

186

273

Age, mean (range) (year)

65.23 (30–89)

70.21 (49–87)

tPSA (ng/ml), mean (range)

13.62 (1.64-136.45)

28.95 (2.85-211.87)

f/tPSA, mean (range)

0.16 (0.03–0.40)

0.13 (0.02–0.43)

PI-RADS v2, median (range)

3 (2–5)

4 (3–5)

Positive core percentage, mean (range)

-

0.41 (0.08-1)

BiopsyGS, median (range)

-

7 (6–10)

ECE reported by MRI

-

25

ECE on postoperative pathology, n

-

113

    reported by MRI, n (%)

-

23 (20.4)

    not reported by MRI, n (%)

-

90 (79.6)

PSM on postoperative pathology, n

-

101

    PSM with ECE, n (%)

-

68 (67.3)

    PSM without ECE, n (%)

-

33 (32.7)

Pathologic stage

-

 

    pT2, n (%)

-

160 (58.6)

    pT3, n (%)

-

113 (41.4)